share_log

F-1: Registration statement for securities of certain foreign private issuers

F-1: Registration statement for securities of certain foreign private issuers

F-1：发行人证券登记表
美股SEC公告 ·  11/20 05:23

Moomoo AI 已提取核心信息

NeuroSense Therapeutics Ltd. (NeuroSense), a clinical-stage biotechnology company, has filed a registration statement with the U.S. Securities and Exchange Commission (SEC) on November 19, 2024, for a potential sale of up to 10,000,000 ordinary shares. The shares include 224,697 shares issued as commitment shares to YA II PN, LTD. (YA) under a Standby Equity Purchase Agreement, and up to 9,775,303 additional shares that may be sold to YA over a 36-month period. The agreement allows NeuroSense to sell up to $30 million in ordinary shares to YA, subject to certain limitations. The filing is part of NeuroSense's efforts to raise capital for advancing clinical development of its lead product candidate, PrimeC, for ALS, and for other corporate purposes. The registration statement's effectiveness is pending, and the sale of shares will be subject to market conditions and other factors.
NeuroSense Therapeutics Ltd. (NeuroSense), a clinical-stage biotechnology company, has filed a registration statement with the U.S. Securities and Exchange Commission (SEC) on November 19, 2024, for a potential sale of up to 10,000,000 ordinary shares. The shares include 224,697 shares issued as commitment shares to YA II PN, LTD. (YA) under a Standby Equity Purchase Agreement, and up to 9,775,303 additional shares that may be sold to YA over a 36-month period. The agreement allows NeuroSense to sell up to $30 million in ordinary shares to YA, subject to certain limitations. The filing is part of NeuroSense's efforts to raise capital for advancing clinical development of its lead product candidate, PrimeC, for ALS, and for other corporate purposes. The registration statement's effectiveness is pending, and the sale of shares will be subject to market conditions and other factors.
NeuroSense Therapeutics Ltd.（NeuroSense）是一家临床阶段的生物技术公司，于2024年11月19日向美国证券交易委员会（SEC）提交了注册声明，计划出售高达10,000,000股普通股。这些股票包括向YA II PN, LTD.（YA）作为承诺股份发行的224,697股，以及在36个月内可能售予YA的最多9,775,303股额外股票。该协议允许NeuroSense向YA出售高达3000万美元的普通股，但需遵循某些限制。此次提交是NeuroSense为推进其主要产品候选PrimeC用于肌萎缩侧索硬化症（ALS）的临床开发而筹集资金的努力之一，亦用于其他公司用途。注册声明的有效性尚在待定中，股票的出售将受市场条件及其他因素的影响。
NeuroSense Therapeutics Ltd.（NeuroSense）是一家临床阶段的生物技术公司，于2024年11月19日向美国证券交易委员会（SEC）提交了注册声明，计划出售高达10,000,000股普通股。这些股票包括向YA II PN, LTD.（YA）作为承诺股份发行的224,697股，以及在36个月内可能售予YA的最多9,775,303股额外股票。该协议允许NeuroSense向YA出售高达3000万美元的普通股，但需遵循某些限制。此次提交是NeuroSense为推进其主要产品候选PrimeC用于肌萎缩侧索硬化症（ALS）的临床开发而筹集资金的努力之一，亦用于其他公司用途。注册声明的有效性尚在待定中，股票的出售将受市场条件及其他因素的影响。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    热议
    美股
    股票代码最新价涨跌幅

    暂无数据

    资讯热榜
    更新时间